-
公开(公告)号：US08613925B2
公开(公告)日：2013-12-24
申请号：US12445753
申请日：2007-10-19
申请人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
发明人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
IPC分类号： A61K39/395
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2317/92
摘要： Antibody antagonists of human interleukin-13 receptor alpha 1 which bind to hIL-13Rα1 through domain 3 of the extracellular region of the receptor and inhibit IL-13 receptor-mediated signaling by IL-13 are disclosed herein. These antibodies have uses inter alia in the treatment or prevention of IL-13-related disorders and diseases. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing hIL-13Rα1-mediated activities are also disclosed.
摘要翻译： 本文公开了通过受体细胞外区域的结构域3结合hIL-13Rα1和IL-13受体介导的信号传导的人白细胞介素-13受体α1的抗体拮抗剂。 这些抗体尤其用于治疗或预防IL-13相关疾病和疾病。 本发明还公开了编码所述抗体分子，载体，宿主细胞和包含抗体分子的组合物的核酸。 还公开了使用抗体分子抑制或拮抗hIL-13Rα1介导的活性的方法。
-
2.发明申请公开(公告)号：US20100285035A1
公开(公告)日：2010-11-11
申请号：US12774966
申请日：2010-05-06
申请人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
发明人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
IPC分类号： A61K39/395 , C07K16/28 , C07H21/04 , A61P35/00 , A61P1/00 , A61P17/06 , A61P11/06 , A61P37/08 , A61P29/00 , A61P17/00 , C12N15/60 , C12N5/10
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2319/43 , C12P21/005
摘要： High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.
摘要翻译： 公开了人白细胞介素-13受体α1的高亲和力抗体拮抗剂。 抗体分子在抑制IL-13Rα1介导的活性中是有效的，因此，在治疗与hIL-13Rα1活性相关的病症中使用所需的拮抗剂。 本发明还公开了编码所述抗体分子，载体，宿主细胞和包含抗体分子的组合物的核酸。 还公开了使用抗体分子抑制或拮抗IL-13Rα1介导的活性的方法。
-
3.发明申请公开(公告)号：US20080166343A1
公开(公告)日：2008-07-10
申请号：US11875017
申请日：2007-10-19
申请人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
发明人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2319/43 , C12P21/005
摘要： High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.
摘要翻译： 公开了人白细胞介素-13受体α1的高亲和力抗体拮抗剂。 抗体分子在抑制IL-13Rα1介导的活性中是有效的，因此，在治疗与hIL-13Rα1活性相关的病症中使用所需的拮抗剂。 本发明还公开了编码所述抗体分子，载体，宿主细胞和包含抗体分子的组合物的核酸。 还公开了使用抗体分子抑制或拮抗IL-13Rα1介导的活性的方法。
-
4.发明授权公开(公告)号：US08568722B2
公开(公告)日：2013-10-29
申请号：US12774966
申请日：2010-05-06
申请人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
发明人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
IPC分类号： A61K39/395
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2319/43 , C12P21/005
摘要： High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.
摘要翻译： 公开了人白细胞介素-13受体α1的高亲和力抗体拮抗剂。 抗体分子在抑制IL-13Rα1介导的活性中是有效的，因此，在治疗与hIL-13Rα1活性相关的病症中使用所需的拮抗剂。 本发明还公开了编码所述抗体分子，载体，宿主细胞和包含抗体分子的组合物的核酸。 还公开了使用抗体分子抑制或拮抗IL-13Rα1介导的活性的方法。
-
公开(公告)号：US20110052597A1
公开(公告)日：2011-03-03
申请号：US12445753
申请日：2007-10-19
申请人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
发明人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
IPC分类号： A61K39/395 , C07K16/24 , C12N15/63 , C12N5/00 , A61P11/06 , A61P17/00 , A61P17/06 , A61P1/00 , A61P19/02
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2317/92
摘要： Antibody antagonists of human interleukin-13 receptor alpha 1 which bind to hIL-13Rα1 through domain 3 of the extracellular region of the receptor and inhibit IL-13 receptor-mediated signaling by IL-13 are disclosed herein. These antibodies have uses inter alia in the treatment or prevention of IL-13-related disorders and diseases. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing hIL-13Rα1-mediated activities are also disclosed.
摘要翻译： 本文公开了通过受体的细胞外区的结构域3结合hIL-13Rα1和IL-13受体介导的信号传导的人白细胞介素-13受体α1的抗体拮抗剂。 这些抗体尤其用于治疗或预防IL-13相关疾病和疾病。 本发明还公开了编码所述抗体分子，载体，宿主细胞和包含抗体分子的组合物的核酸。 还公开了使用抗体分子抑制或拮抗hIL-13Rα1介导的活性的方法。
-
6.发明授权公开(公告)号：US07754213B2
公开(公告)日：2010-07-13
申请号：US11875017
申请日：2007-10-19
申请人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
发明人： Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
IPC分类号： A61K39/395
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2319/43 , C12P21/005
摘要： High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.
摘要翻译： 公开了人白细胞介素-13受体α1的高亲和力抗体拮抗剂。 抗体分子在抑制IL-13Rα1介导的活性中是有效的，因此，在治疗与hIL-13Rα1活性相关的病症中使用所需的拮抗剂。 本发明还公开了编码所述抗体分子，载体，宿主细胞和包含抗体分子的组合物的核酸。 还公开了使用抗体分子抑制或拮抗IL-13Rα1介导的活性的方法。
-
公开(公告)号：US08207304B2
公开(公告)日：2012-06-26
申请号：US12445759
申请日：2007-10-19
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： Antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are useful in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.
摘要翻译： 公开了人白细胞介素-13受体α1的抗体拮抗剂。 抗体分子可用于抑制IL-13Rα1介导的活性，因此，可用于治疗与hIL-13Rα活性相关的病症中所需的拮抗剂。 本发明还公开了编码所述抗体分子，载体，宿主细胞和包含抗体分子的组合物的核酸。 还公开了使用抗体分子抑制或拮抗IL-13Rα1介导的活性的方法。
-
公开(公告)号：US20090285799A1
公开(公告)日：2009-11-19
申请号：US12445759
申请日：2007-10-19
IPC分类号： A61K39/395 , C07K16/28 , C07H21/04 , C12N15/63 , C12N5/10
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： Antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are useful in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.
摘要翻译： 公开了人白细胞介素-13受体α1的抗体拮抗剂。 抗体分子可用于抑制IL-13Rα1介导的活性，因此，可用于治疗与hIL-13Rα1活性相关的病症中所需的拮抗剂。 本发明还公开了编码所述抗体分子，载体，宿主细胞和包含抗体分子的组合物的核酸。 还公开了使用抗体分子抑制或拮抗IL-13Rα1介导的活性的方法。
-
公开(公告)号：US08420093B2
公开(公告)日：2013-04-16
申请号：US13361143
申请日：2012-01-30
申请人： Gene Kinney , William R. Strohl , Zhiqiang An
发明人： Gene Kinney , William R. Strohl , Zhiqiang An
IPC分类号： A61K39/395
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/92
摘要： The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.
摘要翻译： 本发明涉及差异识别衍生的可扩散配体（也称为ADDL）的多维构象的抗体。 本发明的抗体可以区分阿尔茨海默病和对照人脑提取物，并且可用于检测ADDL和诊断阿尔茨海默病的方法。 本抗体还阻断ADDL与神经元的结合，ADDLS的组装和tau磷酸化，并且在用于预防和治疗与淀粉样蛋白的可溶性低聚物相关的疾病的方法中是有用的。 1-42。
-
公开(公告)号：US07811563B2
公开(公告)日：2010-10-12
申请号：US11577426
申请日：2005-10-21
申请人： Paul Acton , Zhiqiang An , Andrew J. Bett , Robert Breese , Elizabeth Chen Dodson , Gene Kinney , William L Klein , Mary P. Lambert , Xiaoping Liang , Paul Shughrue , William R. Strohl , Kirsten Viola , Lei Chang
发明人： Paul Acton , Zhiqiang An , Andrew J. Bett , Robert Breese , Elizabeth Chen Dodson , Gene Kinney , William L Klein , Mary P. Lambert , Xiaoping Liang , Paul Shughrue , William R. Strohl , Kirsten Viola , Lei Chang
IPC分类号： A61K39/395 , C07K16/18 , G01N33/53
CPC分类号： G01N33/5058 , C07K16/18 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/6896 , G01N2333/4709 , G01N2800/2814 , G01N2800/2821
摘要： The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tauphosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.
摘要翻译： 本发明涉及差异识别衍生的可扩散配体（也称为ADDL）的多维构象的抗体。 本发明的抗体可以区分阿尔茨海默病和对照人脑提取物，并且可用于检测ADDL和诊断阿尔茨海默病的方法。 本抗体还阻断ADDL与神经元的结合，ADDL的组装和酪氨酸磷酸化，并且在用于预防和治疗与淀粉样蛋白和可溶性蛋白的可溶性低聚物相关的疾病的方法中是有用的。 1-42。
-
-
-
-
-
-
-
-
-
搜索结果
25 条记录 (耗时 0.034 秒)
